Get the Stockscreener App
37.74
0.34%
-0.13
After Hours:
37.74
Supernus Pharmaceuticals Inc stock is traded at $37.74, with a volume of 194.46K.
It is down -0.34% in the last 24 hours and up +4.20% over the past month.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
See More
Previous Close:
$37.87
Open:
$37.92
24h Volume:
194.46K
Relative Volume:
0.58
Market Cap:
$2.08B
Revenue:
$651.97M
Net Income/Loss:
$59.71M
P/E Ratio:
35.28
EPS:
1.0696
Net Cash Flow:
$172.03M
1W Performance:
+0.67%
1M Performance:
+4.20%
6M Performance:
+30.36%
1Y Performance:
+35.22%
1-Day Range:
$37.27
$38.13
1-Week Range:
$37.08
$38.68
52-Week Range:
$25.53
$39.37
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Name
Supernus Pharmaceuticals Inc
Sector
Phone
301-838-2500
Address
9715 KEY WEST AVENUE, ROCKVILLE, MD
Compare SUPN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
37.74 | 2.08B | 651.97M | 59.71M | 172.03M | 1.0696 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-11-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-03-23 | Resumed | Jefferies | Buy |
| Dec-01-21 | Resumed | Jefferies | Buy |
| Apr-13-21 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jun-15-20 | Resumed | Jefferies | Hold |
| Nov-08-19 | Downgrade | Berenberg | Buy → Hold |
| Nov-07-19 | Downgrade | Stifel | Buy → Hold |
| Nov-06-19 | Downgrade | Jefferies | Buy → Hold |
| Nov-12-18 | Reiterated | B. Riley FBR | Buy |
| Jan-18-18 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-28-17 | Reiterated | B. Riley FBR, Inc. | Buy |
| Dec-04-17 | Upgrade | Janney | Neutral → Buy |
| Nov-08-17 | Upgrade | Stifel | Hold → Buy |
| Oct-19-17 | Initiated | FBR & Co. | Buy |
| Sep-19-17 | Downgrade | Stifel | Buy → Hold |
| Jul-17-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jul-14-17 | Initiated | Janney | Neutral |
| Jun-01-17 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jul-18-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Jul-18-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Feb-08-16 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-15 | Reiterated | Northland Capital | Outperform |
| Oct-28-15 | Initiated | Northland Capital | Outperform |
View All
Supernus Pharmaceuticals Inc Stock (SUPN) Latest News
Supernus Pharmaceuticals, Inc. Enters into Lease Agreement for Approximately 136,016 Square Feet for its New Headquarters with Advent Key West, LLC - Marketscreener.com
Hennion & Walsh Asset Management Inc. Acquires 25,004 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Burney Co. Raises Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by JPMorgan Chase & Co. - Defense World
Despite the downward trend in earnings at Supernus Pharmaceuticals (NASDAQ:SUPN) the stock advances 3.1%, bringing five-year gains to 56% - Simply Wall St
Multiple Sclerosis Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail
SUPN (Supernus Pharmaceuticals) Intrinsic Value: DCF (FCF B - GuruFocus.com
(SUPN) Investment Report - Stock Traders Daily
Supernus Pharmaceuticals (NASDAQ:SUPN) shareholders have earned a 9.4% CAGR over the last five years - Yahoo Finance
Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Cantor Fitzgerald - Defense World
Supernus Pharmaceuticals (NASDAQ:SUPN) Now Covered by Analysts at Cantor Fitzgerald - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Bought by Principal Financial Group Inc. - Defense World
Principal Financial Group Inc. Has $8.90 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Franklin Resources Inc. Increases Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Where are the Opportunities in (SUPN) - Stock Traders Daily
Jane Street Group LLC Cuts Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Barclays PLC Grows Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Geode Capital Management LLC Has $46.22 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Holdings Lifted by Barclays PLC - Defense World
Geode Capital Management LLC Grows Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
HighTower Advisors LLC Takes $264,000 Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Stifel Financial Corp Increases Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Shares Sold by Wellington Management Group LLP - MarketBeat
Fmr LLC Buys 8,499 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
(SUPN) Trading Signals - Stock Traders Daily
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada - GlobeNewswire
Thinking about buying stock in BigBear.ai, Supernus Pharmaceuticals, Collegium Pharmaceutical, Duolingo, or Cryptoblox Technologies? - Marketscreener.com
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.50 Million Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
SUPN (Supernus Pharmaceuticals) 3-Year EPS without NRI Grow - GuruFocus.com
Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap UpWhat's Next? - MarketBeat
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock Is Going Strong But Fundamentals Look Uncertain: What Lies Ahead ? - Simply Wall St
Ashford Capital Management Inc. Trims Stock Holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Quantbot Technologies LP Sells 21,601 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
28,185 Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Bought by Systematic Financial Management LP - MarketBeat
How To Trade (SUPN) - Stock Traders Daily
Charles Schwab Investment Management Inc. Purchases 91,354 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Charles Schwab Investment Management Inc. Acquires 91,354 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus Pharmaceuticals executive sells shares worth $788,436 By Investing.com - Investing.com Canada
Supernus Pharmaceuticals executive sells shares worth $788,436 - Investing.com
Supernus Pharmaceuticals, Inc. Announces FDA Acceptance for Review of New Drug Application for SPN-812 for the Treatment of ADHD - Marketscreener.com
Intech Investment Management LLC Purchases 1,838 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
PDT Partners LLC Buys Shares of 37,110 Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - The Manila Times
C21 Investments Inc (CXXI-CN) QuotePress Release - The Globe and Mail
Big Rock Brewery Inc (BR-T) QuotePress Release - The Globe and Mail
Supernus Pharmaceuticals CEO to Present at Piper Sandler Healthcare Conference | SUPN Stock News - StockTitan
Loomis Sayles & Co. L P Has $47.27 Million Stock Position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
Evertz Technologies Ltd (ET-T) QuotePress Release - The Globe and Mail
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Segall Bryant & Hamill LLC Acquires New Shares in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - MarketBeat
SUPN (Supernus Pharmaceuticals) Operating Margin % : 22.67% (As of Sep. 2024) - GuruFocus.com
Supernus Pharmaceuticals Inc Stock (SUPN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
0.08%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):